Boston's paclitaxel-eluting stent shows in-stent promise
This article was originally published in Clinica
Executive Summary
Boston Scientific's TAXUS III clinical trial assessing its paclitaxel-eluting stent as a treatment for in-stent restenosis has produced promising six-month results, the company reported.